中文摘要：

目的分析人乳头瘤病毒16型（HPV16）早期蛋白E7的B细胞优势表位，并对其进行免疫原性鉴定。方法采用亲水性方案、柔韧性方案、抗原指数方案及表面可能性方案综合评估其B细胞优势表位，并运用固相合成法合成多肽，经RP—HPLC纯化及纯度分析，用质谱进行定性鉴定。以合成肽免疫Balb／c小鼠，进行免疫效果评价。结果综合分析考虑HPV16E71421（P1），HPV16E7 26-37（P2），HPV16 E7 44-51（P3）可能是B细胞优势表位，免疫小鼠后可明显诱导小鼠血清抗体滴度升高，但只有P1和P2产生的抗体与人宫颈癌组织上清液结合呈阳性反应。结论HPV16E7 14-21和HPV16E7 26-37具有较强的免疫原性，可能成为HPV感染肽疫苗的候选表位。

英文摘要：

Objective To analyse and verify the B-cell epitopes derived from E7 antigen of human papillomavirus type 16. Methods The B-cell epitope candidates was predicted basing on analysis of the hydrophilic regions, flexible regions, antigen index and surface probability of the HPVI6 E7 antigen. Peptides were synthesized and purified with RP-HPLC and identified with mass spectrometry. Balb/c mice were immunized with peptides. Serum antibody titers of the mice were tested. Resuls The B-cell epitopes of the HPV16 E7 may be located at E7 14-21 （ P1 ）, E7 26-37 （P2） and E7 46-51 （ P3 ）. These peptides had the ability to raise the mice serum antibody enormously. The antibody induced by P1 and P2 could react with the supernatant of human cervical cancer tissue. Conclusion HPV16 E7 14-21 and HPV16 E7 26-37 had antigenicity, and may be used for the development of peptide vaccine against HPV infection.